1. Petrone L. Osteoporosis in adults with intellectual disabilities. South Med J 2012;105:87-92.
2. Hess M, Campagna EJ, Jensen KM. Low bone mineral density risk factors and testing patterns in institutionalized adults with intellectual disabilities and developmental disabilities. J Appl Res Intellect Disabil 2018;31(suppl 1):157-164.
3. McKinnon I, Lewis T, Mehta N, et al. Vitamin D in patients with intellectual and developmental disability in secure in-patient services in the north of England, UK. BJPsych Bull 2018;42:24-29.
4. Dosa NP, Eckrich M, Katz DA, et al. Incidence, prevalence, and characteristics of fractures in children, adolescents, and adults with spina bifida. J Spinal Cord Med 2007;30(suppl 1):S5-S9.
5. Baer M, Kozlowski B, Blyler E, et al. Vitamin D, calcium, and bone status in children with developmental delay in relation to anticonvulsant use and ambulatory status. Am J Clin Nutr 1997;65:1042-1051.
6. Mazur L, Wilsford L, Rosas L, et al. Low 25-hydroxyvitamin D levels in children with spina bifida. South Med J 2016;109:31-35.
7. Flueck J, Perret C. Vitamin D deficiency in individuals with a spinal cord injury: a literature review. Spinal Cord 2017;55:428-434.
8. Barbonetti A, D'Andrea S, Martorella A, et al. Low vitamin D levels are independent predictors of 1-year worsening in physical function in people with chronic spinal cord injury: a longitudinal study. Spinal Cord 2018;56:494-501.
9. Wilkinson J, Stockley I, Hamer A, et al. Biochemical markers of bone turnover and development of heterotopic ossification after total hip arthroplasty. J Orthop Res 2003;21:529-534.
10. Szulc P, Kaufman J, Delmas P. Biochemical assessment of bone turnover and bone fragility in men. Osteoporos Int 2007;18:1451-1461.
11. Suriawati A, Majid H, Al-Sadat N, et al. Vitamin D and calcium intakes, physical activity, and calcaneus BMC among school-going 13-year old Malaysian adolescents. Nutrients 2016;8:E666.
12. Zubillaga P, Garrido A, Mugica I, et al. Effect of vitamin D and calcium supplementation on bone turnover in institutionalized adults with Down’ syndrome. Eur J Clin Nutr 2006;60:605-609.
13. Penagini F, Borsani B, Maruca K, et al. Short-term vitamin D3 supplementation in children with neurodisabilities: comparison of two delivery methods. Horm Res Paediatr 2017;88:281-284.
14. Greenspan S, Bilezekian J, Watts N, et al. A clinician performance initiative to improve quality of care for patients with osteoporosis. J Womens Health (Larchmt) 2013;22:853-861.
15. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-1130.
16. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab 2012;97:1153-1158.
17. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 2014;25:2359-2381.
18. Chubb SA. Measurement of C-terminal telopeptide of type I collagen (CTX) in serum. Clin Biochem 2012;45:928-935.
19. Sousa-Santos AR, Afonso C, Santos A, et al. The association between 25(OH) D levels, frailty status and obesity in older adults. PLoS One 2018;13:e0198650.
20. Seamans KM, Hill TR, Wallace JM, et al. Cholecalciferol supplementation throughout winter does not affect markers of bone turnover in healthy young and elderly adults. J Nutr 2010;140:454-460.
21. Schwetz V, Trummer C, Pandis M, et al. Effects of vitamin D supplementation on bone turnover markers: a randomized controlled trial. Nutrients 2017;9:E432.
22. Nahas-Neto J, Cangussu LM, Orsatti CL, et al. Effect of isolated vitamin D supplementation on bone turnover markers in younger postmenopausal women: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 2018;29:1125-1133.
23. Wamberg L, Pedersen SB, Richelsen B, et al. The effect of high-dose vitamin D supplementation on calciotropic hormones and bone mineral density in obese subjects with low levels of circulating 25-hydroxyvitamin d: results from a randomized controlled study. Calcif Tissue Int 2013;93:69-77.
24. Bauman WA, Spungen AM, Morrison N, et al. Effect of a vitamin D analog on leg bone mineral density in patients with chronic spinal cord injury. J Rehabil Res Dev 2005;42:625-634.
25. Bauman WA, Emmons RR, Cirnigliaro CM, et al. An effective oral vitamin D replacement therapy in persons with spinal cord injury. J Spinal Cord Med 2011;34:455-460.
26. Sorva A, Valimaki M, Ristelli J, et al. Serum ionized calcium, intact PTH and novel markers of bone turnover in bedridden elderly patients. Eur J Clin Invest 1994;24:806-812.
27. Björkman M, Sorva A, Risteli J, et al. Vitamin D supplementation has minor effects on parathyroid hormone and bone turnover markers in vitamin D-deficient bedridden older patients. Age Ageing 2008;37:25-31.
28. Rossini M, Adami S, Viapiana O, et al. Dose-dependent short-term effects of single high doses of oral vitamin D(3) on bone turnover markers. Calcif Tissue Int 2012;91:365-369.
29. Harlow L, Sahbani K, Nyman JS, et al. Daily parathyroid hormone administration enhances bone turnover and preserves bone structure after severe immobilization-induced bone loss. Physiol Rep 2017;5:e13446.
30. Fuller K, Kirstein B, Chambers TJ. Regulation and enzymatic basis of bone resorption by human osteoclasts. Clin Sci (Lond) 2007;112:567-575.
31. Kim S, Yamazaki M, Zella LA, et al. Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol Cell Biol 2006;26:6469-6486.
32. Ma YL, Cain RL, Halladay DL, et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2001;142:4047-4054.
33. Gu J, Tong XS, Chen GH, et al. Effects of 1α,25-(OH)2D3 on the formation and activity of osteoclasts in RAW264.7 cells. J Steroid Biochem Mol Biol 2015;152:25-33.
34. Mason JJ, Williams BO. SOST and DKK: antagonists of LRP family signaling as targets for treating bone disease. J Osteoporos 2010;2010:460120.
35. Qin W, Zhao W, Li X, et al. Mice with sclerostin gene deletion are resistant to the severe sublesional bone loss induced by spinal cord injury. Osteoporos Int 2016;27:3627-3636.
36. Qin W, Li X, Peng Y, et al. Sclerostin antibody preserves the morphology and structure of osteocytes and blocks the severe skeletal deterioration after motor-complete spinal cord injury in rats. J Bone Miner Res 2015;30:1994-2004.
37. Tatsumi S, Ishii K, Amizuka N, et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 2007;5:464-475.
38. Rolvien T, Krause M, Jeschke A, et al. Vitamin D regulates osteocyte survival and perilacunar remodeling in human and murine bone. Bone 2017;103:78-87.
39. Sankaralingam A, Roplekar R, Turner C, et al. Changes in Dickkopf-1 (DKK1) and sclerostin following a loading dose of vitamin D 2 (300,000 IU). J Osteoporos 2014;2014:682763.
40. Acibucu F, Dokmetas HS, Acibucu DO, et al. Effect of vitamin D treatment on serum sclerostin level. Exp Clin Endocrinol Diabetes 2017;125:634-637.
41. Adami S, Gatti D, Viapiana O, et al. Physical activity and bone turnover markers: a cross-sectional and a longitudinal study. Calcif Tissue Int 2008;83:388-392.
42. De La Piedra C, Diaz Martin MA, Diaz Diego EM, et al. Serum concentrations of carboxyterminal cross-linked teleopeptide of type 1 collagen (ICTP), serum tartrate resistant acid phosphatase, and serum levels of intact parathyroid hormone in parathyroid hyperfunction. Scand J Clin Lab Invest 1994;54:11-15.
43. Noe S, Oldenbuettel C, Heldwein S, et al. Patterns of vitamin D, parathyroid hormone, and C-terminal teleopeptide of collagen type 1 in Caucasian and African descent HIV-infected populations in central Europe. Infect Dis Rep 2017;9:7265.
4. Frighi V, Morovat A, Andrews TM, et al. Vitamin D, bone mineral density and risk of fracture in people with intellectual disabilities. J Intellect Disabil Res 2019;63:357-367.